MGNX News and Press, MacroGenics Inc. From 06/21/22

Gainers: Convey Health Solutions Holdings (CNVY) +139%. Valneva (VALN) +86%. Green Giant (GGE) +78%. CEA Industries (CEAD) +76%. Clovis Oncology (CLVS) +71%. Tabula Rasa HealthCare (TRHC) +34%. Revlon (REV) +34%. Innate Pharma (IPHA) +33%. Sorrento Therapeutics (SRNE) +28%. MacroGenics (MGNX)...

Gainers:Sana Biotechnology (SANA) +9%. Fanhua  (FANH) +8%. Sotera Health Company (SHC) +7%. ON Semiconductor Corporation (ON) +7%. MacroGenics (MGNX) +6%. Losers: Immunovant (IMVT) -7%. FTC Solar (FTCI) -7%. Biote (BTMD) -6%. Cue Health  (HLTH) -5%. Kezar Life Sciences (KZR) -5...

Bluebird Bio (BLUE), Clovis Oncology (NASDAQ:CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out of cash within the next six months. The analysis of 118 companies developing cancer medications exclu...

ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Direc...

Gainers: Bright Health Group BHG +21%. TransMedics Group TMDX +21%. Belite Bio (BLTE) +11%. Sharps Technology STSS +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma CNTB -45%. Amarin AMRN -43%. Kezar Life Sciences (KZR) -35%. MacroGenic...

MacroGenics, Inc. (MGNX) Q1 2022 Earnings Conference Call May 3, 2022 16:30 ET Company Participants Chris James - Vice President, Investor Relations and Corporate Communications Scott Koenig - President and Chief Executive Officer Jim Karrels - Chief Financial Officer Conference Call Particip...

MacroGenics press release (NASDAQ:MGNX): Q1 Non-GAAP EPS of -$1.08 misses by $0.23. Revenue of $11.1M misses by $12.08M. For further details see: MacroGenics Non-GAAP EPS of -$1.08 misses by $0.23, revenue of $11.1M misses by $12.08M

Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors Targeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignancies Conference call sched...

MacroGenics (NASDAQ:MGNX) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, after market close. The consensus EPS Estimate is -$0.85 and the consensus Revenue Estimate is $23.18M (+37.3% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Re...

ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financia...